Q-omics provides the consensus-scored EMX2OS profile across patient tissues and cancer cell-line models. EMX2OS expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EMX2OS is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, EMX2OS RNA expression shows 15,446 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, KICH, and BRCA as cancer lineages where EMX2OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EMX2OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EMX2OS survival associations across molecular data types. EMX2OS RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EMX2OS RNA expression–survival associations across cancer types. High EMX2OS expression shows unfavorable associations in ACC, LUAD and STAD, but favorable associations in KIRC, CESC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EMX2OS RNA expression.
This table summarizes EMX2OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for EMX2OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EMX2OS shows lower tumor expression in KICH, KIRC, UCEC, THCA, BRCA and COAD. The KICH box plot shows higher EMX2OS RNA expression in normal versus tumor tissue (log2 FC = −2.402, t-test p < 0.001).
This table shows molecular features associated with EMX2OS in patient tissues and cancer cell lines. In patient samples, EMX2OS shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
